The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.


For many years, alkylating agents were the standard treatment for chronic lymphocytic leukemia (CLL). The advent of purine analogs improved response rates, but not overall survival, and although the monoclonal antibody rituximab is generally active against B-cell malignancies, it has demonstrated limited benefits as monotherapy for the treatment of CLL… (More)
DOI: 10.1586/14737140.2013.818294


  • Presentations referencing similar topics